Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition

The Washington University

Status: Withdrawn

Conditions: Kwashiorkor; Marasmus

Treatments: Drug: Placebo; Drug: Albendazole

Study type: Interventional

Funder types: Other

Identifiers

NCT01395381

MJM-albendazole

Details and patient eligibility

About

The benefit of anti-worm therapy as part of the case management of severe acute malnutrition (SAM) in the outpatient setting has not previously been studied. This study will compare recovery rates of children with SAM treated in the community with locally-produced ready-to-use therapeutic food (RUTF) with and without prescribed albendazole as part of their case management.

Sex: All

Ages: 6 to 59 months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 12-59 months old
• Kwashiorkor and/or Marasmus
• Qualified for home-based therapeutic feeding with RUTF

Exclusion criteria

• Obvious congenital or other malformation that makes child a poor candidate for feeding with RUTF
• Unable to consume test-dose of RUTF in clinic
• Parent refusal to participate and return for follow-up

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo

Albendazole

Experimental group

Treatment:

Drug: Albendazole